Merck & Co. announced an impending shortage of the adult version of Recombivax HB, its hepatitis B vaccine, because of improvements to its West Point, Pa., facility. The shortfall does not include the pediatric formulation and is not linked to an FDA warning issued in April about production issues at the plant, a Merck spokeswoman said. GlaxoSmithKline is making enough vaccines to address the shortage, the CDC said.

Related Summaries